Latest NewsOct 30, 2025HiFiBiO Therapeutics Announces the Appointment of Leading I&I Experts to its Scientific Advisory BoardAll Filter By: Year20252024202320222021202020192018201720162015Sep 25, 2025HiFiBiO Therapeutics to Present Updated Phase 1 Clinical Data of Two Immuno-Oncology Programs at the 2025 Annual Meeting of the European Society for Medical Oncology (ESMO) Jun 18, 2025HiFiBiO Therapeutics to Present Preclinical Data of Three Leading I&I Programs at the 2025 Annual Meeting of the Federation of Clinical Immunology SocietiesApr 29, 2025HiFiBiO Therapeutics to Present Preclinical Data for A Novel Immunology Antibody at the 2025 Annual Meeting of the Clinical Immunology Society Nov 4, 2024HiFiBiO Therapeutics Receives FDA Clearance of IND Application for HFB200604, a Best-in-Class BTLA Agonist Antibody for the Treatment of Inflammatory and Immunology Diseases Oct 7, 2024HiFiBiO Therapeutics to Showcase DIS® Enabled Translational Insights from Ongoing Phase 1 Clinical Trials for Two Novel Immuno-Oncology Antibodies at the 2024 Annual Meeting of the Society for Immunotherapy of Cancer (SITC)1 2 3 … 18 >
